Carrimycin tablets: Carrimycin tablets are administered 400mg a day orally for 7 days.
Study summary
This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Met HLH-2004 diagnostic criteria;
* Active infection;
* Empirical treatment with carbapenems did not respond after 72 hours;
* Age \>18 years old, no gender limitation;
* Ability and willingness to adhere to the study visit schedule and all protocol requirements.
Exclusion Criteria:
* Other antibiotics should be selected according to the results of drug sensitivity;
* Systemic antibiotics other than carbapenems are used with 72 hours;
* Inability to take oral medications due to disease of gastrointestinal tract;
* Severe liver insufficiency;
* Expected survival time \< 1 month;
* Pregnant or breasting-feeding women;
* Allergic to Carrimycin tablets;
* Active hepatitis B or hepatitis C infection;
* Patients with HIV infection;
* Patients with other contraindications considered unsuitable for participation in this study.
Primary outcome measure(s)
Cure rates of infections — 1 week and 2 weeks after initiation of treatment The percentage of participants having clinical cure
Overall response rate of HLH — 2 weeks after treatment Overall response rate includes complete remission (CR) and partial remission (PR)
Trial sites (1)
Facility
City
Region
Status
Beijing Friendship Hospital, Capital Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.